About
Carina Kern is a geneticist and biotechnology executive focused on aging biology, resilience loss, and AI-enabled drug discovery. She is the founder and CEO of LinkGevity, a Cambridge-affiliated biotech at the Babraham Research Campus developing anti-necrotic therapeutics and longevity-related drug programs. She also serves on Lifeboat Foundation advisory boards including the Life Extension Board.
Areas of interest
longevitybiotechdrug discoveryaging biologyAI for biologyspace biologykidney diseaseorgan preservationgeneticschronic disease